Aprea Therapeutics, Inc. (APRE)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Oren Gilad Ph.D. | Co-Founder, CEO, President & Director | 796.95k | -- | 1968 |
| Mr. John P. Hamill CPA | Senior VP, CFO, Principal Accounting Officer & Secretary | 610.23k | -- | 1964 |
| Dr. Dansu Li Ph.D. | Head of Technology | -- | -- | -- |
| Dr. Lars B. Abrahmsen Ph.D. | Senior VP & Chief Scientific Officer | -- | -- | 1957 |
| Mr. Brian Wiley | Senior Vice President of Corporate Development & Strategy | -- | -- | 1968 |
| Dr. Michel Afargan Ph.D. | Head of Pharmacology Development | -- | -- | -- |
| Mr. Ze'ev Weiss B.Sc., C.P.A. | Chief Business Advisor | -- | -- | 1962 |
| Dr. Nadeem Q. Mirza M.D., M.P.H. | Executive Officer | -- | -- | -- |
| Ms. Andrea Epstein | Controller | -- | -- | -- |
Aprea Therapeutics, Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 7
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Corporate Governance
Upcoming Events
November 7, 2024 at 10:59 AM UTC - November 11, 2024 at 12:00 PM UTC
Aprea Therapeutics, Inc. Earnings Date
Recent Events
September 10, 2024 at 1:00 PM UTC
at HC Wainwright Global Investment Conference - On-Demand
April 25, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission